Although most PI3K inhibitors show a boosting effect on anticancer immunity, it is anticipated that selective PI3K inhibitors can maximally enhance host immunity against cancer and minimize deleterious effects on normal tissues. This evidence concerns the gene PIK3CA and cancer.